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Summary 
The concept of “at risk mental state” for psychosis arose from previous work 
attempting to identify a putative psychosis prodrome. This article summarises the 
current criteria used to identify such individuals, such as the Ultra High Risk criteria, 
and the further identification of important clinical risk factors or biomarkers to 
improve prediction of who might develop a psychotic disorder. We also discuss the 
important ethical issues in classifying and treating such individuals, current treatment 
trials in this area and what treatment current services can offer to these patients.  
 
 
Learning objectives 
 Understand the development, refinement and use of tools attempting to 
identify a putative psychosis prodrome or “at risk mental state” 
 
 Appreciate the ethical issues in identifying and treating individuals with an “at 
risk mental state” for psychosis 
 
 Consider the treatment options in light of the ethical issues, the research trials 
and what current services can offer 
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Background 
It has long been known that the majority of psychotic disorders do not develop de 
novo. There is invariably a period of non-specific or low-grade symptoms or 
“prodrome” prior to the onset of a frank psychosis. In medicine, a prodrome is an 
early symptom (or set of symptoms) that might indicate the start of a disease before 
specific symptoms occur. A common example would be measles, which is described 
as having a prodrome of 3-4 days consisting of non-specific symptoms such as fever, 
coryzal symptoms, conjunctivitis, and cough. This is then followed by the specific 
rash, making the definitive diagnosis possible. 
 
Attempts to identify a prodrome in psychosis are not new. The notion of being able to 
prevent the onset of schizophrenia and other psychotic disorders by detecting and 
intervening in the prodromal phase has been a goal discussed for many years 
(Sullivan 1927). Chapman and others have previously outlined the developing 
symptoms of schizophrenia (Chapman 1966, Yung, 1996) retrospectively. They are 
often non-specific symptoms such as depression, anxiety and disturbance in sleep as 
well as psychotic symptoms which are not fully formed or fleeting. In this review we 
will summarise the work to date on attempts to prospectively identify the prodrome 
concentrating on the so called “at risk mental state” group, including the effectiveness 
of interventions. This is especially important to UK psychiatrists at present as the new 
mental health targets for psychosis include this group so services for these patients 
may become more widespread (Marwaha, 2015). 
 
Identification of a putative prodrome 
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In the mid-1990’s researchers attempted to characterize or identify a “putative 
prodrome” for psychosis prospectively. This was prompted by a critique of the DSM 
III prodrome category, the emerging early intervention in psychosis paradigm and 
further retrospective accounts of prodromal symptoms in first episode psychosis 
patients. This led to the idea that identifying an “At Risk Mental State” (ARMS) for 
psychosis, based on some of the reported prodromal symptoms, may be useful in 
order to predict subsequent development of a psychotic disorder. The goal was to 
identify a group at imminent high risk of developing a psychotic disorder, using a 
combination of genetic and clinical risk factors (Yung, 2003). Criteria have since 
been developed to attempt to identify this group such as the “Ultra High Risk” (UHR) 
criteria (Yung, 2004a) or the similar “Clinical High Risk” (CHR) (Miller, 2003) 
criteria; those meeting these criteria are deemed to have an “At Risk Mental State” 
(ARMS) for psychosis. In this article we will refer to this group as UHR as this was 
the initial criteria, developed in Melbourne, Australia and is most commonly used in 
the UK. The criteria were named Ultra High Risk to distinguish this help-seeking 
clinical group from other high risk populations such as those with a genetic risk. The 
UHR criteria in brief consist of three groups: (1) Attenuated Psychotic Symptoms 
(APS): Presence of attenuated (subthreshold for a diagnosis of a psychotic disorder) 
psychotic symptoms within the previous 12 months. (2) Brief Limited Intermittent 
Psychotic Symptoms (BLIPS): history of brief self-limiting psychotic symptoms in 
the previous 12 months, which spontaneously resolve (within 7 days). (3) Trait group 
(FH): genetic vulnerability to psychotic disorder (either schizotypal personality 
disorder or family history of psychotic disorder in a first degree relative) and a drop in 
functioning or persistent low functioning for at least one month within the previous 12 
months (criteria shown in Box 1). Age is also a criteria, as this focuses on those in the 
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highest epidemiological risk period for development of psychosis. In Melbourne, the 
age range is currently 15-25 and most of the research cited below focuses on this 
youth population. 
 
The initial studies using these criteria suggested that they identified a group with a 
high risk of transition to (development of) a full threshold psychotic disorder, defined 
as full psychotic symptoms occurring for over 1 week, which was taken as the 
threshold for when clinicians would generally start treatment. A recent meta-analysis 
of transition to a psychotic disorder from studies in this population, using a varieties 
of similar tools for measuring the at risk mental state, reported rates of 18% after 6 
months of follow-up, 22% after 1 year, 29% after 2 years, and 36% after 3 years 
(Fusar-Poli, 2012). These risks are around 400 times the population risk of 
development of psychosis. The risks also appear to continue over a longer-term period 
(Nelson, 2013). 
 
Rating scales have been developed and validated to assess and identify those who 
meet the UHR criteria. The most widely used scale is the Comprehensive Assessment 
of At Risk Mental Sates (CAARMS), (Yung, 2005) developed in Melbourne, 
although the similar Structured Interview for Prodromal symptoms (SIPS) and the 
associated Scale of Prodromal Symptoms (SOPS) (Miller, 2003) are more often used 
in the United States and some other international centres. These scales focus on the 
positive symptoms of psychosis (disordered beliefs, perceptions and speech) as the 
way of indexing risk clinically. 
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The basic symptoms and self-disturbance approach 
A different approach to understanding and characterising the prodrome has been 
proposed by European research groups that highlight the importance of subtle 
subjective alterations in cognition, memory and thinking that may be manifest many 
years before the onset of a psychotic disorder (Huber, 1989); these have been termed  
“basic symptoms”. Research groups have developed assessment tools to identify those 
presenting with such symptoms (e.g. the Schizophrenia Proneness Instrument (SPI-A) 
(Schultze-Lutter 2007)) and individuals meeting basic symptoms criteria also have a 
much higher risk of developing a psychotic disorder over a longer term period (if at 
least one of the 66 basic symptoms was present at baseline, a specificity of 0.59, a 
sensitivity of 0.98, a PPV of 0.70, and an NPV of 0.96 for developing schizophrenia 
at 9.6 year follow-up resulted) (Klosterkotter, 2001). Some research groups have 
combined the two concepts and classified those who meet these basic symptoms 
criteria as an early initial prodrome stage, with the UHR criteria identifying a late 
initial prodromal stage (Bechdolf, 2012). A further related set of criteria examine the 
disturbance of the sense of self in putatively prodromal patients using tools such as 
the Examination of AnomolousAnomalous Self-Experience (EASE) (Parnas, 2005). 
We will concentrate on the UHR/ARMS concept in this article as it is more widely 
used in UK practice, although the approach does relatively neglect those presenting 
with cognitive problems or negative symptoms. At present, the assessment and 
criteria for identification of basic symptom and self disturbances require considerable 
training and are therefore less accessible to clinicians in practice but remains an 
interesting area of research development.  
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Problems with the UHR criteria and improving predictive power  
Despite the initial enthusiasm with regard to the ability to prospectively identify high 
risk individuals there were criticisms, especially when intervention and treatment 
strategies were proposed for this group. Firstly, although the transition rates were high, 
it was still the case that more than half of the identified individuals would not develop 
psychosis in 12 months.  This may not be an issue for some disorders but, for a 
potentially stigmatizing disorder such as psychosis, especially if treatment is 
considered, this is important. There were also reports that the rate of transition to 
psychosis may not be as high as first thought. This appears to be a particular problem 
in established clinics where the transition rates have declined over time (Yung, 2007). 
There are a number of explanations for this but one important factor is the population 
from which the sample is drawn. Similar to any diagnostic test, the positive predictive 
power of these criteria is affected by the population prevalence of the disorder. 
Therefore, if these criteria were applied to a non help-seeking population sample then 
they would (and do) have a lower predictive power than if they were used in a sample 
referred to an early psychosis clinic but not quite meeting the criteria for a psychotic 
disorder. This has been discussed in the literature (Yung, 2007). In response to this 
there have been attempts to see if the predictive power of these criteria can be 
improved either using clinical factors and/or biomarkers.  
 
A study of 104 UHR individuals reported by the group in Melbourne investigated 
whether particular clinical or demographic factors, in addition to the UHR criteria, 
could be used to improve the prediction of which UHR individuals would develop a 
psychotic disorder (Yung, 2004b).  Four baseline clinical predictors of transition to 
psychosis were identified: a combination of attenuated psychotic symptoms and 
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genetic risk; a long duration of symptoms prior to baseline; poor social functioning; 
and poor attention. A model requiring the presence of at least one of these four 
potential predictors gave a good predictive validity with a positive predictive value 
(PPV) of 80.8% and a sensitivity and specificity of 60.0% and 92.6% respectively. 
Belonging to at least one of the three inclusion groups and belonging to the Brief 
Limited Intermittent Psychotic Symptoms (BLIPS) group also increased the risk of 
transition. 
 
The North American Prodrome Longitudinal Study (NAPLS) consortium  
investigatedconsortium investigated the predictive power of a large number of 
variables using their pooled sample of 291 cases (Cannon, 2008). This was a 
particularly important study given that one of the methodological difficulties in UHR 
research to that point had been that of small sample sizes. They found that five 
variables were strong predictors of transition to psychosis and that when these 
variables were combined the PPV was as high as 81%, without a substantial 
compromise in sensitivity or specificity. These predictors had substantial, but not 
complete, overlap with the predictors found from the earlier Melbourne study 
described above. Three of the five variables were found to be associated with 
transition in a replication study: high unusual thought content scores on the rating 
scales; low functioning; and having genetic risk with functional decline (Thompson, 
2011). 
 
The EPOS group, again using multisite data, investigated predictors in a European 
sample. They reported a high positive predictive value (83.3%) for a 6 variable model 
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that included higher positive symptoms, bizarre thinking, sleep disturbances, 
schizotypal personality disorder, Global Assessment of Functioning (GAF) score and 
years of education. They also reported a different and innovative method of assessing 
“risk” in terms of using a prognostic index, which enables the risk of individual 
patients to be calculated (Rurhmann, 2010). The addition of UHR criteria and basic 
symptom criteria has also been shown to increase the predictive power for transition 
to psychosis as well as the related subjective symptoms of self-disturbance (Nelson, 
2012).  
 
Interestingly, in a study again from the PACE clinic in Melbourne, the initial 
judgments of experienced clinicians as to whether an individual meeting UHR criteria 
and admitted to the clinic would subsequently develop psychosis were adequate (a 
sensitivity of 0.80, specificity of 0.84, positive predictive value of 0.32) but not 
extremely accurate predictors so caution about the accuracy of clinical prediction 
based on “praecox feeling” was recommended (Nelson, 2010). In summary, it appears 
that additional specific clinical factors such as specific positive psychotic symptoms, 
poor functioning, negative symptoms and subtle disturbances in cognition or sense of 
self may improve the prediction of the UHR criteria further. Further categorizing 
these individuals with individual risk profiles is an area of research development. 
 
 
Risk factors or biomarkers 
A number of biomarkers or phenotypic markers have been investigated to see if they 
can increase the predictive ability of UHR criteria. Biomarkers of note include 
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structural imaging changes, such as parahippocampal grey mater volume (Mechelli, 
2011) with studies synthesizing data from multiple sites confirming the role 
neuroanatomical changes may have in the prediction of psychosis (e.g. Koutsouleris, 
2015).   In addition, functional neuroimaging has also been utilized to predict 
psychosis – both in measuring in vivo neurochemistry as well as with task and resting 
state fMRI.   Functional imaging changes which may predict psychosis include 
changes in prefrontal and cortical function on the verbal fluency task, and its relation 
to dopamine levels, (Allen, 2012, Fusar-Poli, 2011), improvement in left inferior 
frontal gyrus function correlated with reduction in prodromal symptoms 
longitudinally (Fusar-Poli, 2011), and, on functional analysis of networks, a change in 
the centrality of the anterior cingulate cortex in the network predicts those at risk who 
may go on to develop a psychotic illness (Lord, 2012).  Using PET and MRS to study 
neurochemical changes, reduction in pre-synaptic dopamine levels (Howes, 2011) 
predicted transition and lower levels of thalamic glutamate islower levels of thalamic 
glutamate are associated with a poorer functional outcome (Allen, 2015).   
Electrophysiological markers such as p300, sensory gating and Mismatch Negativity 
(MMN) have all been shown to be impaired in those at risk for psychosis, with 
particularly strong evidence that MMN can predict onset of disorder (Bodatsch, 2015).  
Other biomarkers include inflammatory and oxidative stress markers and genetic 
variants such as the neuregulin gene (Keri, 2009). A recent study found 15 markers 
including inflammation, oxidative stress, hormones, and metabolic analytes 
potentially served as a blood assay to predict psychosis (Perkins, 2015). Phenotypic 
markers include social cognitive and neurocognitive deficits such as poor theory of 
mind, poor working memory or executive functioning and verbal fluency (Giuliano, 
2012). However, none of these at present are used practically in routine clinic settings, 
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although research is on going to attempt to combine some of these markers with 
clinical factors to be of use to clinicians. 
 
Intervention studies 
There have now been a number of randomized clinical trials of interventions in the 
UHR group, ranging from antipsychotics to CBT, and omega 3 fatty acids, with the 
main aim to prevent or delay the onset of psychosis. These are shown in Table 1. For 
pharmacological interventions we have restricted included trials to placebo-controlled 
designs. There are currently three meta-analyses comparing these treatments on the 
outcome of transition to a full threshold psychotic disorder (Preti, 2010, Stafford, 
2013, van der Gaag, 2013) suggesting there is some promise for all current 
interventions and the meta-analysis of Van de Gaag and colleagues reported a 
Number Needed to Treat (NNT) of 9 to prevent psychosis at 12 months. Early 
enthusiasm for the use of low dose antipsychotic was tempered by the non-trivial rates 
of side effects (weight gain with olanzapine and extra-pyramidal symptoms with 
risperidone) (McGlashan, 2006, McGorry, 2002) and the short-term reduction of the 
transition rate not being maintained over time (Phillips, 2007). Similarly, initial 
enthusiasm in small trials with CBT (Morrison, 2004) have been followed by less 
striking results (at least on transition rates) in larger trials (Morrison, 2012) although 
other trials have found more positive results on transition rates (van der Gaag, 2012). 
A single placebo controlled trial of omega three fatty acids (Amminger, 2010) was 
particularly promising but initial results from the first of two replication studies failed 
to find a significant positive effect in terms of transition to psychosis or symptom 
improvement (McGorry et al, 2015). Further non-randomized trials have suggested 
the benefits of antidepressant medications (Cornblatt, 2007) and Amisulpiride in a 
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non-placebo controlled design  (Ruhrmann, 2007). The efficacy of other 
pharmacological interventions such as glycine and non-pharmacological approaches 
such as family therapy as treatments are currently being investigated. One issue with 
all trials that specifically target a diminished transition rate is whether the intervention 
results in a transition time shifted to after trial end or whether protection rendered is 
long term. 
 
Evidence of a decreased rate of transition to psychotic disorder in recent years (Yung, 
2007) has resulted in many more intervention trials in the UHR group possibly being 
underpowered. In a number of recent trials the standard befriending, supportive 
therapy, active monitoring or case-management strategies have fared as well as the 
intervention strategy when the outcome has been transition to a psychotic disorder. 
This has prompted some involved in these trials to suggest an alternative view to the 
studies simply being underpowered, that the relatively non-specific “control” 
interventions such as active monitoring and supportive therapy (that are not in fact 
treatment as usual but low grade interventions) may be effective in some individuals 
who meet the UHR criteria (Morrison, 2012), McGorry, 2013).  
 
Ethical issues 
 
It is worth highlighting again that the idea of treating psychotic symptoms very early 
in the prodrome and in UHR patients has been the subject of much discussion from 
both clinical and ethical perspectives (Yung, 2007). Some feel that the approach 
advocates treating people too early and labelling and/or potentially stigmatising 
individuals (Yang, 2013) when less than 50% will develop a psychotic disorder in the 
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short to medium term. These are the so-called ‘false positive’ at-risk individuals – i.e. 
those who are not prodromal for psychosis ultimately and therefore there is the risk of 
over-treatment. Also, where antipsychotics are used as an intervention, there is a risk 
of iatrogenic dopamine sensitization, symptom rebound on drug withdrawal and brain 
changes on exposure to neuroleptics. More recently, attention has turned to the 
persistence and development of other psychiatric disorders in this group and the poor 
functional outcome of these patients regardless of whether they develop psychosis 
(Lin, 2015). The percentage of patients meeting UHR criteria who meet the criteria 
for another mental disorder is high. This reinforces the idea that these individuals may 
be at risk for psychosis but are also certainly at risk of other poor outcomes (Lin, 
2015). This has led to discussion about the need to target functioning as well as a 
defined psychosis threshold in this population. 
 
There was much debate amongst all stakeholders during the preparation for the DSM-
5 manual as to whether ARMS criteria should be including in the main body of the 
diagnostic manual. The debate centred on whether it was premature to include this as 
a disorder based on the current predictive validity of the criteria (Yung, 2010). A 
version of the UHR criteria termed “Attenuated Psychosis Syndrome”, was eventually 
included, but in section III or the conditions for further study section of DSM-5, 
indicating further study is needed prior to possible inclusion in the main document. 
Some have argued that the DSM 5 diagnosis of “Other Specified Schizophrenia 
Spectrum Disorder and Other Psychotic Disorders, 298.8 (F28 ICD-10)” includes the 
above as a disorder. The APS criteria are shown in Box 2 and will be subject to 
further field trials prior to the next revision of DSM. 
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A further ethical concern many clinicians working in this area routinely come into 
contact with is the tension between reassurance and normalization of the unusual 
experiences with the follow-up and monitoring present in high-risk services, and 
genuine appreciation of risk. The monitoring, and care offered, may themselves 
impact on anxiety, appraisals, etc., and thus may have the paradoxical effect of 
increasing, rather than decreasing, the rate of transition in an at risk group if not 
delivered in services with certain levels of skill and expertise. Expanding clinical 
awareness and service delivery may lead to this and other unwanted, and unforeseen, 
outcomes, one of which may be how the criminal justice systems decides to treat an 
offender who demonstrates the Attenuated Psychosis Syndrome: will it be viewed as a 
mental disorder, with all the attendant consequences to both to the patient, the courts, 
and the clinicians? Or will the legal system see it as the risk state it is? More subtle 
ethical issues lie around how one talks about risk with young people deemed to be at 
risk. As noted above, the majority of such individuals may not develop a frank 
psychosis if followed-up. Hence, should clinicians who work in early detection 
consider whether patients have a right not to know their prognosis? One could argue 
that given we have no specific treatments that have clearly demonstrated to have 
altered clinical course there may be no positive benefit in knowing. Further, there are 
the possible harms of self-stigmatization and fear from the potential diagnosis. 
Despite these issues, many would argue that if sensitive and appropriate interventions 
can delay or reduce the impact of developing psychosis, even in a minority of 
individuals, that this is warranted given the impact for most individuals of a psychotic 
disorder. 
 
Current specialised UHR services  
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Although the concept of UHR or ARMS has been more widely accepted, there are 
few services that provide specific interventions to these patients in the UK. Service 
provision is mostly aligned to the Early Intervention in Psychosis (EIP) services and 
not stand-alone services. The OASIS service in South London and EDIT services in 
Birmingham and Manchester and the CAMEO service in Cambridge are notable 
exceptions of specific UHR teams.  These services often have a strong research focus. 
Worldwide there has been considerable expansion of these services and this trend 
seems likely to continue. Specialised clinics offer CBT focused intervention along 
with case management and medical treatment of co-morbidities. An example of an 
approach from the specialized PACE clinic in Melbourne is shown in Box 3. These 
specialized clinics have been shown to be cost-effective, (Valmaggia, 2009) which 
has added to the argument for providing specific services for these patients. 
Assessment and treatment of UHR patients has been included as part of the new 
Department of Health waiting time standards for first episode psychosis (Department 
of Health, 2014).  
 
What should a clinician do where no specialised services are available? 
What are the options then for clinicians who see such patients in their clinic and do 
not have the option of referring them to a specialized service? Often the local EI team 
will have a policy on what treatment to suggest and may provide an assessment using 
the CAARMS or a similar tool. However, often this is a “watch and wait” approach 
and the level of specific intervention is minimal. The issue of risk needs to be handled 
sensitively as highlighted above. As a psychiatrist, the temptation might be to start 
someone with sub-threshold symptoms on a low dose of an antipsychotic, especially 
when other non-pharmacological interventions are not available. The current research 
 17 
suggests that a) more than half of these patients will not develop a psychotic illness 
even in the long term and therefore we may be treating a high proportion 
inappropriately and not in fact delaying or reducing transition to psychosis b) whilst 
we have some indicators of those at highest risk our current tools and clinical 
predictors are less than perfect. On balance the suggestion is that antipsychotics 
should not be used in the first instance. Current Iinternational Early Psychosis 
guidelines also suggest that antipsychotics should not be first line but “if rapid 
worsening of psychotic symptoms occurs together with significant deterioration in 
functioning related to these symptoms and elevated risk to self or others, a low-dose 
atypical antipsychotic may be considered, in conjunction with close monitoring and 
support” (Early Psychosis Guidelines Writing Group 2010). This is also supported by 
the National Institute for Health and Care Excellence (NICE) adult Psychosis and 
schizophrenia in guideline (NICE, 2014), which states “Do not offer antipsychotic 
medication to people considered to be at increased risk of developing psychosis or 
with the aim of decreasing the risk of or preventing psychosis”. Treating the common 
co-morbidities such as depression and anxiety, if at treatment thresholds, are 
definitely warranted and a more watchful waiting approach is advised, as diagnostic 
uncertainty is common. The beneficial effects of high dose omega three fatty acids 
initially seemed promising and relatively side-effect free but recent research does not 
appear to have replicated the initial promising findings. In services where specialised 
psychological interventions are available, CBT would be appropriate. CBT 
approaches in UHR often focus on other difficulties such as depression and anxiety 
rather than simply psychotic symptoms (see Box 3).  
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For some patients, often whose symptoms are exacerbated by stress or drug use, more 
practical solutions offered in the process of assessment or in care-coordination, or 
interventions for substance misuse can have beneficial effects.  
The recent NICE guideline for adults with Psychosis and Schizophrenia now includes 
the following recommendations on treatment of at risk patients: 1) offer individual 
cognitive behavioural therapy (CBT) with or without family intervention; 2) offer 
interventions recommended in NICE guidance for people with any of the anxiety 
disorders, depression, emerging personality disorder or substance misuse (NICE, 
2014). 
 
Conclusions 
Attempts to prospectively identify individuals at very high risk of developing a 
psychotic disorder have considerably advanced the research knowledge on both the 
mechanism of development of psychosis and approaches to very early or indicated 
intervention. Whilst there was initial enthusiasm with regard the ability to identify and 
treat clinical presentations such as the UHR state, some caution with regard to the 
predictive validity and the consequences of using such labels in respect to this validity 
has been raised. Further refining of the criteria including both the use of biomarkers, 
phenotypes and clinical features represents the next step in the pathway towards the 
overall goal of altering the course of psychotic disorders.   
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Box 1: the Melbourne UHR criteria (from (Nelson, 2012)) 
The Melbourne Ultra High Risk Criteria: (1) Must Be Aged Between 15 and 25 Years; (2) Have 
Been Referred to a Specialized Service for Help; (3) Have Experienced a Drop in Functioning of 
At Least 1 Month Over the Last Year or Sustained Low Functioning and (4) Meet the Criteria for 
One or More of the Following 3 Groups 
Group 1: Attenuated Psychotic Symptoms: 
 Presence of at least one of the following symptoms:   ideas of reference, odd beliefs or magical 
thinking, perceptual disturbance, paranoid ideation, odd thinking and speech, odd behavior, and 
appearance 
 Frequency of symptoms: at least several times a week  
 Recency of symptoms: present within the last year  
 Duration of symptoms: present for at least 1 week and no longer than 5 years 
 
Group 2: Brief Limited Intermittent Psychotic Symptoms (BLIPS) 
 Transient psychotic symptoms 
 Presence of at least one of the following: ideas of reference, magical thinking, perceptual 
disturbance, paranoid ideation, odd thinking, or speech 
 Duration of episode: less than 1 week   
 Frequency of symptoms: at least several times per week  
 Symptoms resolve spontaneously   
 Recency of symptoms: must have occurred within the last year 
 
Group 3: Trait vulnerability group 
 Schizotypal personality disorder in the identified individual or a first-degree relative with   a 
psychotic disorder 
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Box 2: The Criteria for Attenuated Psychosis Syndrome from the DSM5 research 
appendix section III – disorders for further study   
Box 2: Criteria for Attenuated Psychosis Syndrome in DSM 5 
 
All 6 of the following 
 A.    At least one of the following symptoms are present in attenuated form with 
relatively intact reality testing, but of sufficient severity and/or frequency to 
warrant clinical attention:        
 1.     delusions/delusional ideas            
 2.     hallucinations/perceptional abnormalities            
 3.     disorganized speech/communication  
 B.     Symptoms in Criterion A must be present at least once per week for the past 
month.  
 C.    Symptoms in Criterion A must have begun or worsened in the past year.  
 D.     Symptoms in Criterion A are sufficiently distressing and disabling to the 
individual and/or legal guardian to lead them to seek help.  
 E.     Symptoms in Criterion A are not better explained by any other DSM-5 
diagnosis, including Substance-Related Disorders.  
 F.     Clinical criteria for a Psychotic Disorder have never been met. 
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Box 3: Treatment approach from Specialised UHR services (the Melbourne group)  - 
adapted from the PACE group manual (PACE writing group, 2012) 
 
 
1) Assessment, formulation and engagement 
2) Psychoeducation 
3) Individual case management – includes 
 Ongoing monitoring of the client’s mental state and risks. 
 Ensuring the client and family or carers are appropriately informed about the nature of the mental health issues and 
their treatment. 
 Reducing the trauma or anxiety associated with any necessary inpatient admissions. 
 Facilitating adequate treatment for comorbid disorders. 
 Assisting in reducing any adverse impact of the illness on the client’s psychosocial environment, for example in 
relationships, accommodation, education, employment, financial security. 
 Fostering the recovery of the client, reintegration into society, and restoration of a normal developmental trajectory. 
 Risk assessment and management 
 
4) Family interventions 
5) CBT using a stress vulnerability model 
 stress management 
 positive symptoms 
 depression/negative symptoms 
 basic symptoms 
 co-morbidities 
6) Appropriate medical treatment of co-morbidities (e.g. depression, anxiety disorders) 
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